Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital

Efficacy and Safety of Glimepiride With or Without Linagliptin Treatment in Patients With HNF1A Diabetes (Maturity-Onset Diabetes of the Young Type 3): A Randomized, Double-Blinded, Placebo-Controlled, Crossover Trial (GLIMLINA)

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review


  1. Beta-hydroxybutyrate suppresses hepatic production of the ghrelin receptor antagonist, LEAP2

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Effect of Meal Texture on Postprandial Glucose Excursions and Gut Hormones After Roux-en-Y Gastric Bypass and Sleeve Gastrectomy

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. THERAPY OF ENDOCRINE DISEASE: Amylin and calcitonin - physiology and pharmacology

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  4. LEAP2 reduces postprandial glucose excursions and ad libitum food intake in healthy men

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Long-acting amylin analogues for the management of obesity

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

Vis graf over relationer

OBJECTIVE: Sulfonylureas are first-line treatment of hepatocyte nuclear factor 1-α (HNF1A) diabetes (maturity-onset diabetes of the young type 3), but many patients do not achieve optimal glycemic control without episodes of hypoglycemia. We investigated the combination of the sulfonylurea glimepiride and the dipeptidyl peptidase 4 inhibitor linagliptin versus glimepiride monotherapy with respect to glycemic variability, glycemic control, and risk of hypoglycemia.

RESEARCH DESIGN AND METHODS: In a randomized, double-blinded, crossover trial, patients with HNF1A diabetes (n = 19; mean ± SD age 43 ± 14 years, BMI 24.8 ± 2.8 kg/m2, and glycated hemoglobin [HbA1c] 7.4 ± 0.2% [57.1 ± 7.3 mmol/mol]) were randomly assigned to treatment with glimepiride + linagliptin 5 mg (16 weeks), washout (4 weeks), and glimepiride + placebo (16 weeks) (or vice versa). Glimepiride was titrated targeting a fasting plasma glucose of 4.5-6.0 mmol/L without hypoglycemia. Treatments were evaluated by continuous glucose monitoring (CGM), HbA1c, and meal test.

RESULTS: Compared with glimepiride + placebo, glimepiride + linagliptin did not significantly improve the primary end point, mean amplitude of glycemic excursions (MAGE) (mean difference -0.7 mmol/L, P = 0.1540), but displayed significant reductions in coefficient of variation on CGM (-3.6%, P = 0.0401), HbA1c (-0.5%, P = 0.0048), and glimepiride dose (-0.7 mg/day, P = 0.0099). β-cell glucose sensitivity (assessed as C-peptide-to-glucose ratio) during meal test improved with glimepiride + linagliptin. Incidences of hypoglycemia were similar with both treatments.

CONCLUSIONS: Linagliptin as add-on treatment to glimepiride improved glycemic variability and control without increasing risk of hypoglycemia in patients with HNF1A diabetes.

TidsskriftDiabetes Care
Udgave nummer9
Sider (fra-til)2025-2033
Antal sider9
StatusUdgivet - sep. 2020

Bibliografisk note

© 2020 by the American Diabetes Association.

ID: 61381668